Shani J, Livshitz T, Wenzel M
Int J Nucl Med Biol. 1985;12(1):13-9. doi: 10.1016/0047-0740(85)90006-3.
This paper demonstrates modification of organ distribution of a radiopharmaceutical, acetyl-103Ru-ruthenocene, by competing drugs. This radiopharmaceutical concentrates in kidneys of male Wistar rats 15-fold higher than in females of the same strain and age. This concentration in the male is age-dependent. Moreover, the retention of that radiopharmaceutical in male rats' kidneys is markedly reduced by pre-treatment of the rats with estradiol, and this effect is dose-dependent. Estradiol is competetively inhibiting the retention of acetyl-ruthenocene by the kidneys, the same effect also being obtained by tamoxifen, an anti-estrogen used clinically for regression of mammary carcinoma. Blocking the retention of acetyl-ruthenocene was also obtained by testosterone and cyproterone-acetate, as well as by ovariectomy, but the block after castration was partially compensated with time. Blood clearance of acetyl-ruthenocene is biphasic, with a first t 1/2 of about 12 h, and a second t 1/2 of about 48 h. The retention of the label is sex-specific also in mice, but only the female mice show a high adrenal affinity and significant changes in its organ distribution. These effects may be due to competition of acetyl-ruthenocene for steroid receptors, or due to its activation of enzymes that are responsible for its transformation into a bindable moiety.
本文证明了竞争药物对放射性药物乙酰 - 103Ru - 钌茂的器官分布的改变。这种放射性药物在雄性Wistar大鼠肾脏中的聚集量比相同品系和年龄的雌性大鼠高15倍。雄性大鼠体内的这种聚集量与年龄有关。此外,用雌二醇预处理大鼠后,该放射性药物在雄性大鼠肾脏中的滞留量明显减少,且这种作用呈剂量依赖性。雌二醇竞争性抑制肾脏对乙酰钌茂的滞留,临床上用于乳腺癌消退的抗雌激素他莫昔芬也有同样的效果。睾酮、醋酸环丙孕酮以及卵巢切除也能阻止乙酰钌茂的滞留,但去势后的阻止作用会随时间部分得到补偿。乙酰钌茂的血液清除呈双相性,第一个半衰期约为12小时,第二个半衰期约为48小时。在小鼠中,标记物的滞留也具有性别特异性,但只有雌性小鼠表现出对肾上腺的高亲和力以及其器官分布的显著变化。这些作用可能是由于乙酰钌茂与类固醇受体竞争,或者是由于其激活了负责将其转化为可结合部分的酶。